Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification

J. Krejci, M. Pesek, P. Grossmann, M. Krejci, J. Ricar, L. Benesova, M. Minarik,

. 2011 ; 8 (3) : 135-8.

Jazyk angličtina Země Řecko

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027593

Case reports on the co-incidence of Kirsten rat sarcoma (KRAS) mutation and epidermal growth factor receptor (EGFR) amplification in patients with NSCLC are very rare. This combination is usually considered a negative prognostic factor, despite EGFR amplification alone having positive predictive value. The whole course of treatment of a patient with both EGFR amplification and KRAS mutation present is decribed. The patient in question was a smoker for whom both first- and second-line chemotherapy had been unsuccessful. In stage IV disease biological therapy was administered and proved highly beneficial. Today, 38 months since commencing the treatment, the patient still has no signs of progression and the therapy is still in progress.

000      
00000naa a2200000 a 4500
001      
bmc12027593
003      
CZ-PrNML
005      
20130115112130.0
007      
ta
008      
120817s2011 gr f 000 0#eng||
009      
AR
035    __
$a (PubMed)21518819
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Krejci, J $u Department of Tuberculosis and Respiratory Diseases, Charles University, University Hospital in Pilsen, Pilsen, Czech Republic. jana.krejci@gmail.com.
245    10
$a Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification / $c J. Krejci, M. Pesek, P. Grossmann, M. Krejci, J. Ricar, L. Benesova, M. Minarik,
520    9_
$a Case reports on the co-incidence of Kirsten rat sarcoma (KRAS) mutation and epidermal growth factor receptor (EGFR) amplification in patients with NSCLC are very rare. This combination is usually considered a negative prognostic factor, despite EGFR amplification alone having positive predictive value. The whole course of treatment of a patient with both EGFR amplification and KRAS mutation present is decribed. The patient in question was a smoker for whom both first- and second-line chemotherapy had been unsuccessful. In stage IV disease biological therapy was administered and proved highly beneficial. Today, 38 months since commencing the treatment, the patient still has no signs of progression and the therapy is still in progress.
650    _2
$a adenokarcinom $x farmakoterapie $x genetika $x radioterapie $7 D000230
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a geny ras $7 D011905
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a nádory plic $x farmakoterapie $x genetika $x radioterapie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a chinazoliny $x terapeutické užití $7 D011799
650    _2
$a erbB receptory $x genetika $7 D066246
650    _2
$a výsledek terapie $7 D016896
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pesek, M
700    1_
$a Grossmann, P
700    1_
$a Krejci, M
700    1_
$a Ricar, J
700    1_
$a Benesova, L
700    1_
$a Minarik, M
773    0_
$w MED00180194 $t Cancer genomics & proteomics $x 1790-6245 $g Roč. 8, č. 3 (2011), s. 135-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21518819 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20130115112241 $b ABA008
999    __
$a ok $b bmc $g 949635 $s 784939
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 8 $c 3 $d 135-8 $i 1790-6245 $m Cancer genomics & proteomics $n Cancer Genomics Proteomics $x MED00180194
LZP    __
$a Pubmed-20120817/11/03

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace